Home › Alpha-1 Antitrypsin Deficiency › California
Alpha-1 Antitrypsin Deficiency clinical trials in California
4 studies for Alpha-1 Antitrypsin Deficiency are looking for participants at sites in California.
Cities in California
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
- University of California San Diego, La Jolla
- UCLA Pulmonary and Critical Care, Los Angeles
- University of California Benioff Children's Hospital, San Francisco
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 12, 2026 · NCT06165341A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 100, Los Angelas
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Oct 26, 2026 · NCT07555483Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
- University of California San Diego, Altman Clinical and Translational Institute, La Jolla
- UCLA Pulmonary and Critical Care, Los Angeles
- Stanford University, Palo Alto
- and 1 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated May 13, 2026 · NCT05677971PiMZ Longitudinal Cohort (PiMZ Logic)
- University of California- Los Angeles, Los Angeles
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT06505603From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.